Community-based data show that increasing categories of severity of hypertension according to the 2017 ACC/AHA BP Guidelines are associated with increasing risk of CVD events in middle age.
A post-hoc analysis of the ARISTOTLE trial showed safety and efficacy of apixaban compared to warfarin in AF patients aged 55 years or older with multi-morbidity.
A small cross-sectional study showed an age-associated rise in BP starting in childhood in a more Westernized community, compared to an isolated, non-acculturated community.
AHA 2018 VITAL evaluated both vitamin D and omega-3 supplementation and did not find effect on the primary cancer and CV endpoints. Secondary endpoints suggest lower total MI with omega-3 suplementation.
AHA 2018 Adm. Giroir emphasizes the importance for anyone of being physically active, and how recommended levels can easily be achieved. This is important for individual health, but also for national security.
AHA 2018 Deepak Bhatt considers the compounds that were tested in the VITAL and REDUCE-IT trials, which yielded neutral and very positive results, respectively, and what likely caused this discrepancy.
AHA 2018 U.S. Department of Health & Human Services and AHA teamed up to engage entire communities to be more physically active, by highlighting the evidence that shows that health will benefit from it.
AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.
AHA 2018 Paul Ridker outlines how the new CIRT results add to our understanding of inflammation biology in relation to CV risk and how this directs future studies of inflammation.
Structural brain abnormalities are more common in patients with prediabetes compared with non-diabetics, and even more common in T2DM patients.
AHA 2018 Dorairaj Prabhakaran showed improved quality of life and return to pre-infarct daily activities with the Yoga-CaRe program as replacement for cardiac rehabilitation in post-MI patients.
AHA 2018 Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors, and with a modest decrease in MACE in those with existing ASCVD.